MoneyWorks4Me

Everest Organics - Quaterly Results

11 Nov 2022 Evaluate
Revenue showed a marginal decline at Rs. 459.72 millions. For the quarter ended September 2022, as compared to corresponding quarter of last year.The Total Profit for the quarter ended September 2022 of Rs. 9.39 millions grew from Rs.-13.44 millionsOperating Profit saw a handsome growth to 29.93 millions from 3.25 millions in the quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 459.72 467.49 -1.66 890.00 980.78 -9.26 2000.47 1815.67 10.18
Other Income 2.17 15.14 -85.67 6.05 16.43 -63.18 22.11 10.62 108.19
PBIDT 29.93 3.25 820.92 17.44 46.68 -62.64 86.39 239.05 -63.86
Interest 8.50 8.16 4.17 15.43 15.38 0.33 31.03 32.56 -4.70
PBDT 21.43 -4.91 -536.46 2.01 31.30 -93.58 55.36 206.49 -73.19
Depreciation 11.31 10.10 11.98 21.17 19.72 7.35 37.97 33.75 12.50
PBT 10.12 -15.01 -167.42 -19.16 11.58 -265.46 17.39 172.74 -89.93
TAX 0.73 -1.57 -146.50 -1.00 3.70 -127.03 5.96 35.59 -83.25
Deferred Tax 0.73 1.13 -35.40 -1.00 1.80 -155.56 3.06 5.39 -43.23
PAT 9.39 -13.44 -169.87 -18.16 7.88 -330.46 11.43 137.15 -91.67
Equity 80.00 80.00 0.00 80.00 80.00 0.00 80.00 80.00 0.00
PBIDTM(%) 6.51 0.70 836.49 1.96 4.76 -58.83 4.32 13.17 -67.20
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..